ASCO 2017: LATITUDE trial of abiraterone for metastatic prostate cancer doubles median PFS

3 Jun 2017
ASCO 2017: LATITUDE trial of abiraterone for metastatic prostate cancer doubles median PFS

Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%.

In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months.

The study will be featured in a press briefing today and presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

“There is a large unmet need to improve treatment for men with newly diagnosed metastatic cancer, who die of the disease within less than five years on average,” said lead study author Karim Fizazi MD, PhD, head of the Department of Cancer Medicine at Gustave Roussy, University Paris-Sud in Villejuif, France. “The benefit from early use of abiraterone we saw in this study is at least comparable to the benefit from docetaxel chemotherapy, which was observed in prior clinical trials, but abiraterone is much easier to tolerate, with many patients reporting no side effects at all.”

Prostate cancer growth is fueled by testosterone. Androgen deprivation therapy, or ADT, is active against prostate cancer by preventing testicles from making testosterone.

Despite ADT, the adrenal glands and prostate cancer cells continue making small amounts of androgens.

Abiraterone stops production of testosterone throughout the body by blocking an enzyme that converts other hormones to testosterone.

The FDA previously approved abiraterone for patients with metastatic prostate cancer that worsened despite ADT.

LATITUDE is a multinational, randomised placebo-controlled phase III clinical trial of men with newly diagnosed, high-risk metastatic prostate cancer who had not previously received ADT.

All patients had at least two of three risk factors: Gleason score (a measure of tumour grade) of 8 or more, 3 or more bone metastases, or 3 or more visceral metastases (spread to other organs in certain areas of the body, such as the liver).

The patients were randomly assigned to receive ADT plus abiraterone and prednisone or ADT plus placebo.

Corticosteroid prednisone is routinely given with abiraterone to manage certain side effects of abiraterone, such as low potassium or high blood pressure.

At a median follow up of 30.4 months, men who received abiraterone had a 38% lower risk of death than those who received placebo.

The median overall survival had not yet been reached in the abiraterone group (meaning that more than 50% of patients in that group were still alive at the time of analysis, so a median survival could not be calculated) and was 34.7 months in the placebo group.

Abiraterone was also associated with a 53% lower risk of the cancer worsening than the placebo and resulted in cancer growth being delayed by a median of 18.2 months.

Several severe side effects were more common with abiraterone acetate and prednisone than placebo: high blood pressure (in 20% vs. 10% of men), low potassium level (10.4% vs 1.3%), and liver enzyme abnormalities (in 5.5% vs. 1.3% of men).

“We need to be cautious when using abiraterone in men who have an increased risk for heart problems, such as those with diabetes,” said Dr. Fizazi.

“We had been treating metastatic prostate cancer the same way for 70 years until docetaxel chemotherapy was shown to improve survival in 2015, and now in 2017 we show abiraterone is also helping patients live longer,” said Dr. Fizazi. “The next step is to see if adding abiraterone on top of docetaxel offers further benefit,” a study which is currently ongoing in Europe.

Watch the press conference coverage here.

Source: ASCO 2017